A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

In a landmark medical achievement, NYU Langone Health in the United States has successfully carried out the world's first lung transplant from an HIV-positive donor to an HIV-positive recipient.

Researchers described the procedure carried out on 56-year-old Bertrand Nelson, living with HIV for nearly 26 years, as a "watershed moment for the HIV-positive community". They noted that the medical feat could significantly expand the pool of organ donors available to people living with HIV.

"While these transplants are still only allowable under certain research protocols, this marks an expansion of options for people in need of a lifesaving organ," said Sapna Mehta, Clinical Director of the NYU Langone Transplant Institute.

A New Frontier in Organ Transplantation

Also read: HIV No Longer Barrier To Organ Transplants, Say Delhi Doctors After Successful Kidney Surgery

The transplant was performed under research protocols established through the 2013 HIV Organ Policy Equity (HOPE) Act, which allows organs from HIV-positive donors to be transplanted into HIV-positive recipients in approved research settings.

According to the researchers, while HIV-positive donor transplants involving hearts and abdominal organs have been performed previously, this was the first time such a procedure was successfully carried out for the lungs.

"Transplantation of hearts and abdominal organs has been done before, but this has not been done in lung transplantation," said Mark A. Sonnick, transplant pulmonologist at NYU Langone Transplant Institute.

Approximately 1.2 million people in the United States are living with HIV. Thanks to modern antiretroviral therapy (ART), most people with HIV can now live long, healthy lives, have near-normal life expectancy, and are unable to transmit the virus when treatment is effective.

Bertrand Nelson Gets Dual-Organ Transplant

Nelson was diagnosed with both HIV and sarcoidosis, an inflammatory disease that can affect multiple organs, particularly the lungs, in 2000. At the time, doctors said the condition was in remission.

However, in 2021, Nelson contracted Legionnaires' disease, a severe form of pneumonia that required weeks of hospitalization. The illness reactivated his sarcoidosis, which subsequently spread to his liver.

By 2024, his condition had deteriorated significantly. He required increasing amounts of oxygen to breathe and was referred to the NYU Langone Transplant Institute for evaluation for both lung and liver transplantation.

Following assessment under the HOPE Act research program, Nelson was approved for a dual-organ transplant.

On March 21, surgeons transplanted both a new set of lungs and a new liver during the same operation, making medical history.

Read More: Australia’s H5N1 Detection Marks End Of Last Virus-Free Continent

Life After Surgery

In a statement, NYU Langone said Nelson is doing well after the complex surgery.

"Nelson is now off oxygen for the first time in four years and getting back in shape after years of limited mobility," the statement read.

Nelson credited his mother, who will turn 82 in August, for her unwavering support throughout his health struggles.

"I want to be well for her," Nelson said. "I want her to see me thriving."

Hope for People Living With HIV

Nelson hopes his experience will encourage others and draw attention to the need for greater access to organ transplantation within the HIV community.

"There are so many others who need access to this level of care, and the more organs that become available, the better the odds of finding the right match and living a long life," he said.

Can People With HIV Get A Transplant?

As per the US National Institutes of Health, people with HIV can successfully donate or receive transplanted organs with reasonable success rates.

However, health care providers must consider and monitor potential drug interactions, kidney and liver function, and HIV viral suppression in people with HIV receiving a transplant. Further, the NIH advised HIV positive patients to continue taking all prescribed HIV medicines before and after transplant.

The ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) has surpassed 1,000 confirmed cases, according to the latest update from the country's Health Ministry.

In a statement posted on X, the ministry said as of June 20, the outbreak has resulted in 1,003 confirmed cases and 254 deaths, with a case fatality rate of 25.3 per cent

More than 100 people have recovered from the disease, while 365 patients are currently in isolation or receiving hospital treatment.

"The threshold of 1,000 confirmed cases has been crossed. Despite this progression, response teams continue active investigations, epidemiological surveillance, and prevention actions in affected areas," the ministry said.

"The response to the Ebola virus disease continues in the provinces of Ituri, North Kivu, and South Kivu, with an improvement in the number of recoveries but a decrease in the contact follow-up rate," the ministry added.

Health Workers Increasingly Affected

Also read: Australia’s H5N1 Detection Marks End Of Last Virus-Free Continent

The outbreak is also taking a growing toll on healthcare workers. According to the DRC's National Public Health Institute, at least 78 nurses, doctors, and other healthcare workers have contracted the disease during the outbreak, and 18 have died.

Abdou Sebushishe, medical lead in Congo for the International Medical Corps, said all infected healthcare workers were exposed outside dedicated Ebola treatment facilities, Bloomberg reported.

The current outbreak involves the Bundibugyo strain of Ebola, which often begins with symptoms similar to malaria and other common illnesses.

Because early symptoms can be difficult to distinguish, healthcare workers may come into contact with infected patients before Ebola is suspected and strict infection-control measures are implemented.

Sebushishe said infections among healthcare workers have been linked to several factors, including:

• Inadequate infection-control practices
• Shortages of personal protective equipment (PPE)
• Limited training for healthcare staff
• Weak disease surveillance systems in health facilities.

Israel Reports 2 Suspected Cases

Meanwhile, Israel's Health Ministry has reported two suspected Ebola cases involving individuals who recently returned from Congo.

Officials stressed that Ebola infection has not yet been confirmed, and laboratory testing is underway. Results are expected in the coming days, according to local media reports.

The ministry said it is conducting an epidemiological investigation to identify contacts and assess any potential links between the suspected cases.

According to the Health Ministry, Israel has never recorded a confirmed Ebola case. During the major West African Ebola outbreak in 2014, several suspected cases were investigated, but all ultimately tested negative.

Read More: WHO Sounds Alarm on Europe's Extreme Heat: Here's How Hot It Could Get Across Countries

What Is Ebola?

Ebola is a severe and often fatal viral hemorrhagic fever first identified in 1976. Since then, more than 30 outbreaks have been recorded, primarily in Central and West Africa.

Common symptoms include:

• Fever
• Headache
• Weakness and fatigue
• Vomiting
• Diarrhea
• Muscle pain
• Sore throat
• Unexplained bleeding or bruising

In severe cases, the disease can lead to organ failure, internal bleeding, shock, and death. Aid organizations warn that without stronger surveillance, expanded testing, faster laboratory turnaround times, and more effective contact tracing, the outbreak could continue to grow in the coming weeks and months.

Australia has officially lost its status as the last continent free of the H5N1 bird flu virus after authorities confirmed the highly pathogenic strain on the mainland.

The highly contagious H5N1 variant of avian influenza has now been detected on every continent, marking a significant moment in the disease's global spread.

H5N1 Confirmed In Two Wild Birds

The virus was first detected in a migratory seabird, a brown skua, found on a beach in Cape Le Grand National Park near Esperance in Western Australia, around 700 km southeast of Perth.

Authorities later confirmed a second positive case in a northern giant petrel found on a remote beach along Western Australia's south coast.

Agriculture Minister Julie Collins said testing conducted by the Commonwealth Scientific and Industrial Research Organization (CSIRO) confirmed both birds were infected with H5N1 avian influenza.

"We all knew we couldn't be bird flu-free forever," Collins told a press conference.

No Evidence of Widespread Outbreak Yet

Also read: WHO Sounds Alarm on Europe's Extreme Heat: Here's How Hot It Could Get Across Countries

Despite the discovery, officials say there is currently no evidence of mass wildlife deaths or spread into Australia's poultry industry.

Collins said Australian poultry and agricultural systems remain free of bird flu and authorities are investigating whether the virus has become established in local wildlife populations.

"We are working to determine whether the H5 bird flu has established in the wildlife of Australia, other than these two isolated birds," she said.

Samples from the infected birds will undergo further analysis over the coming week as researchers look for signs of transmission to other species.

Further, Western Australia's Chief Veterinary Officer Michelle Rodan said authorities had received 58 reports of sick or dead birds through an emergency hotline between Friday and Sunday afternoon. Nine samples have so far been collected for testing.

Why Australia Had Remained H5N1-Free

Read More: Father's Day: AI Now Reading Sperm, Giving Hope of Fatherhood to Infertile Men

Until now, Australia was the only continent where the H5N1 strain had not been detected. Although the virus has circulated across Asia since the 1990s and reached Antarctica in 2024, Australia had remained unaffected.

According to Dr. Michelle Wille, ARC Future Fellow at the University of Melbourne, Australia's unique bird migration patterns likely delayed the virus's arrival.

"There are no duck species which routinely migrate between Australia and Asia, nor are there ducks that migrate through Antarctica," Wille wrote in The Conversation.

However, evidence suggests other seabirds—including gulls, skuas and giant petrels—may have helped carry the virus over long distances across Antarctica and subantarctic regions, eventually bringing it closer to Australia, he said.

Why H5N1 Is A Concern

Read to Know: How Climate Change Is Increasing the Global Disease Burden | Explained

H5N1 is a highly pathogenic strain of avian influenza that can spread rapidly among poultry and wild bird populations, causing severe disease and high mortality rates in birds.

While human infections remain rare, they can occur through direct and unprotected contact with infected birds, animals, or contaminated environments.

Although severe human cases have historically shown a mortality rate of around 50%, sustained human-to-human transmission has not been observed.

How To Protect Yourself

Health authorities recommend the following precautions:

• Avoid direct contact with sick or dead wild birds and other animals whenever possible.
• Observe wildlife from a safe distance.
• Wear appropriate personal protective equipment (PPE) if handling sick or dead birds or animals is unavoidable.
• Avoid touching surfaces contaminated with bird droppings, saliva, mucus, litter, or bedding from infected or suspected animals.
• Do not consume raw milk or raw milk products, particularly from animals suspected or confirmed to be infected with avian influenza.
• Report sick or dead birds to local authorities if encountered.